Document:

PATENT LICENSE
                                       AND
                               TRADEMARK AGREEMENT

Effective June 15, 2000, Retrac Medical, Inc., a Delaware corporation whose
business address is 22 South Main St., New City, New York 10956 ("Retrac"), and
Safe Tech Medical Products, Inc., a Texas corporation whose business address is
673 1 Ashmore Drive, Houston, Texas, and Michael L. Haining, whose address also
is 673 1 Ashmore Drive, Houston, Texas (collectively "Safetech"), agree as
follows:

                                    ARTICLE I
                                   BACKGROUND

         1.1 Safetech represents that it is the owner of all rights, title and
interests in United States Patents Nos. 5,401,245; 5,527,306; 5,785,693; and
5,533,983; and all divisions, continuations, continuations-in-part, reissues and
extensions thereof; and all applications or patents related thereto or based
thereon filed or issued in the United States and in any foreign country or
jurisdiction, including but not limited to Canada, China, Japan, Mexico,
Belgium, Denmark, France, Germany, Italy, The Netherlands, Switzerland, and the
United Kingdom, all of which are identified in Exhibit A hereto (hereinafter
collectively "the Patents").

         1.2 Safetech represents that it has identified various marks, trade
names or brand names for needless connector-products covered by the Patents
which it has used or intended to use in commerce, including STAT-LINK and
STAT-VIAL CONNECTOR, as well as others, all of which are identified in Exhibit B
hereto (hereinafter collectively "the Marks").

         1.3 Safetech desires to grant to Retrac an exclusive, worldwide license
under the Patents and all existing and future modifications and enhancements
thereto, and to the exclusive use of certain Resources of Safetech as defined
hereafter, and to transfer to Retrac all rights it may have in the Marks,
subject to the terms of this Agreement.

         1.4 Retrac desires to receive an exclusive, worldwide license under the
Patents and all existing and future modifications and enhancements thereto, and
to the Resources, and to obtain all available rights in the Marks, pursuant to
the terms of this Agreement.

                                   ARTICLE II
                                   DEFINITIONS

         2.1 Safetech and Retrac are hereafter commonly referred to as "parties"
(in singular and plural usage, as required by the context).

         2.2 Terms defined in this Article 1I shall have their defined meaning
throughout this Agreement.

         2.3 "Licensed Subject Matter" shall mean the subject matter covered by
the Patents, all existing and future modifications and enhancements thereto, and
the Resources.

                                       1
<PAGE>

         2.4 "Resources" shall mean any and all information, equipment and
expertise possessed by Safetech that may assist Retrac to make, use, sell or
offer for sale the Licensed Subject Matter, including but not limited to
engineering design documentation, trade secrets, know how, product prototype and
production tooling, FDA and other governmental approval certifications, and
clinical research reports.

         2.5 "Confidential Information" shall mean (1) trade secrets and other
proprietary information; (2) information marked or designated as confidential;
(3) information, whether or not in written form and whether or not designated as
confidential, which is known to as being treated as confidential; and (4)
information provided by third parties which a party is obligated to keep
confidential. Confidential Information includes, but is not limited to,
products, designations, devices, techniques, data, formulas, discoveries, ideas,
designs, logos, drawings, specifications, models, data, programs, documentation,
know-how, customer lists, marketing methods, plans, strategies, operations,
revenues, expenses, profits, sales, key personnel, customers, suppliers, pricing
policies, and any other information concerning the business affairs of the
parties to this License Agreement.

         2.6 "Licensed Products" shall mean any product covered by, or
manufactured in accordance with, a valid and enforceable claim of one of the
Patents.

         2.7 "Gross Profit" shall mean the selling price at which a customer is
invoiced by Retrac in the usual course of business for Licensed Products less
the cost of goods sold; provided, however, the Gross Profit shall not include,
and there shall be deducted from the computation of Gross Profit for determining
royalty payments due under this Agreement, that portion of the selling price
attributable to (i) freight, (ii) insurance for the Licensed Products, (iii)
sales or use taxes, (iv) tariff duties, (v) amounts credited on returns, (vi)
commissions paid, (vii) charges for "pass-through items" purchased from third
parties regardless of whether a "mark-up" is charged, (viii) marketing costs
associated with the advertising, promotion, distribution and sale of the
product, (ix) discounts actually allowed, (x) accessories not necessary for the
practice of the invention claimed the Patents.

                                   ARTICLE III
                                  LICENSE GRANT

         3.1 BASIC GRANT. Safetech does hereby grant, and Retrac does hereby
accept, subject to the terms and conditions of this Agreement, an exclusive
license to make, use, sell and offer for sale, in the United States and in all
foreign countries and jurisdictions, devices and methods embodying subject
matter claimed in any and all valid and enforceable claims of the Licensed
Subject Matter, and the exclusive fight to use, in the U.S. and in all foreign
countries and jurisdictions, the Resources.

         3.2 SUB-LICENSES. The license granted pursuant to this Agreement shall
include the right to grant sub-licenses at the sole discretion of Retrac,
subject to the terms of this Agreement.

                                       2
<PAGE>

                                   ARTICLE IV
                                  COMPENSATION

         4.1 CASH AND STOCK. Retrac shall pay to Safetech One Million Seven
Hundred Twenty-Five Thousand Dollars ($1,725,000.00) in cash and stock, as
follows:

                (a) Within 30 days of the close of an IPO Retrac shall pay to
Safetech Three Hundred Seventy Five Thousand Dollars ($375,000.00) in cash.

                (b) Within thirty (30) days after the close of an IPO, Retrac
shall reissue to Safetech One Million Three Hundred Fifty Thousand Dollars
($1,350,000.00) in restricted common stock of Retrac as valued at the opening
IPO price.

         4.2 ROYALTY. Retrac shall pay to Safetech nine percent (9.0%) of the
Gross Profit realized by Retrac on Licensed Products sold during the first five
years after the effective date of this Agreement. Thereafter, for the remaining
life of each of the Patents, Retrac shall pay to Safetech eight percent (8.0%)
of the Gross Profit realized by the Retrac on Licensed Products sold.

                                    ARTICLE V
                               PATENT MAINTENANCE

         5.1 MAINTENANCE FEES AND ANNUITIES. Safetech shall, at its own expense,
timely pay all maintenance fees and annuities necessary to keep the Patents in
force for the respective maximum lives of all of the Patents.

         5.2 NOTICE TO RETRAC. Safetech shall notify Retrac in writing when a
maintenance fee is due and when it has been paid.

                                   ARTICLE VI
                         WARRANTIES AND REPRESENTATIONS

         6.1 RIGHT TO MAKE AND PERFORM AGREEMENT. Safetech represents and
warrants that it has full power and authority to enter into and perform this
Agreement and to make the conveyances herein, and that the person signing this
Agreement on Retrac's behalf has been duly authorized and empowered to enter
into this Agreement.

         6.2 OWNERSHIP OF PATENTS AND RESOURCES - NO CONFLICT. Safetech
represents and warrants that it exclusively owns and possesses proper legal
title to the Patents and the Resources, that it is under no present obligation
to any third party with respect to the Patents and the Resources and that it
shall not assume any future obligation to any third party with respect to the
Patents or the Resources, or that may impair any of Retrac's fights under this
Agreement.

         6.3 NO LIENS OR SECURITY INTERESTS. Safetech further represents and
warrants that the Patents and Resources are free from any liens and security
interests.

                                       3
<PAGE>

                                   ARTICLE VII
                                 CONFIDENTIALITY

         7.1 ACKNOWLEDGMENT OF CONFIDENTIALITY. The parties acknowledge that in
the course of conducting negotiations leading to the execution of this License
Agreement and in the course of exercising the rights and carrying out the
responsibilities specified herein, the parties have had and will have access to
Confidential Information of the other party and acknowledge the receipt thereof.

         7.2 PROTECTION OF CONFIDENTIAL INFORMATION. Except where otherwise
provided in accordance with this License Agreement, the parties shall take all
steps reasonable and prudent to protect the Confidential Information of the
other party from access by any other persons and shall not disclose the
Confidential Information of the other party to any other persons without
express, prior written authorization from the other party and under a written
Confidentiality Agreement binding the other persons to the terms as this License
Agreement.

         7.3 INJUNCTIVE RELIEF. The parties agree that in the event of a breach
of the confidentiality obligation under this Article VH by one party, the
non-breaching party will suffer irreparable harm and that monetary damages may
be inadequate to compensate for such breach. Accordingly, the parties shall, in
addition to any other remedies available at law or in equity, be entitled to
injunctive relief to enforce the terms of this Article VII.

                                   ARTICLE VIII
                          IMPROVEMENTS AND ENHANCEMENTS

         8.1 DEVELOPMENTS BY SAFETECH. The license granted under this Agreement
shall extend to all improvements and enhancements made by Safetech to the
subject matter of the Patents and needless connectors generally, without any
additional royalty or other cost to Retrac.

         8.2 RIGHT TO DEVELOP. Retrac shall have the right to improve and
enhance the Licensed Subject Matter, and develop products embodying such
improvements and enhancements.

         8.3 RIGHTS IN IMPROVEMENTS AND ENHANCEMENTS. Retrac shall retain all
rights to any improvements and enhancements to the Licensed Subject Matter made
by Retrac, including but not limited to patent rights and rights under trade
secret law.

                                   ARTICLE IX
                               PATENT ENFORCEMENT

         9.1 ENFORCEMENT BY SAFETECH. In the event Retrac notifies Safetech of a
person Retrac believes is infringing one or more of the Patents, Safetech shall,
within ten days of such notification notify Retrac as to what, if any, action
Safetech intends to take regarding the alleged infringement.

         9.2 ENFORCEMENT BY RETRAC. Retrac, at its sole discretion and at its
expense, may, but is not obligated to, prosecute infringement of any of the
Patents, and shall retain all recoveries and awards as a result of such action;
provided, Retrac shall first give Safetech ten days prior written notice of
Retrac's intent to enforce one or more of the Patents and Safetech, within that
ten day period, may instead elect to enforce the Patents itself. In the event
that Retrac elects to enforce one or more of the Patents, the legal fees and
expenses of such enforcement shall be deductible by Retrac from royalties due
Safetech, and Retrac may join Safetech as a complainant in such action.

                                       4
<PAGE>

                                    ARTICLE X
                             ACCOUNTING AND PAYMENTS

         10.1 STATEMENTS. On or before the ninetieth (90th) day following the
last day of each calendar quarter occurring during the term of this Agreement,
Retrac shall furnish to Safetech a written statement specifying the total
quantity of Licensed Products sold by Retrac during the preceding calendar
quarter, the invoiced amount for each such Licensed Product (including a
computation of deductions) and a computation of the total royalties due. A
similar statement shall be rendered and payment made within ninety (90) days
after and as of the date of termination of this Agreement covering the period
from that covered by the immediately preceding statement to the date of
termination. Safetech shall treat all such statements as confidential.

         10.2 PAYMENTS. By the date on which each statement of subsection 10.1
is due, Retrac shall make payment to Safetech of the royalties due from such
sales.

         10.3 RECORDS. Retrac shall keep true and accurate records, files and
books of account containing all of the data reasonably required for the full
computation and verification of the royalties to be paid hereunder and the
information and reports to be provided Safetech under this Agreement. After
reasonable notice, Retrac shall permit the aforesaid records, files and books of
account to be adequately examined at Retrac's offices at 22 South Main St., New
City, New York 10956 and extracts made therefrom annually during usual business
hours, by a Certified Public Accountant appointed by Safetech and at Safetech's
expense. The first annual examination/audit may be made by Safetech at any time
after the first quarterly report required in subsection 10.1. Safetech shall
treat any and all information learned from such examination/audit as
confidential.

                                   ARTICLE XI
                          NOTICES, PAYMENTS AND REPORTS

         11.1 NOTICES. All notices for all purposes and reports under this
Agreement shall be given or made by mailing the same by registered or certified
mail return receipt requested or by Express Mail or comparable overnight
delivery service, (the date of confirmed delivery to the recipient is to be
considered the effective date of such Notice), addressed in the following
manner:

                                       5
<PAGE>

         IF TO SAFETECH:

                  Safe Tech Medical Products, Inc.
                  6731 Ashmore Drive
                  Houston, Texas

         IF TO RETRAC:

                  Retrac Medical, Inc.
                  22 South Main St.
                  New City, New York 10956

or to such other address as either of the parties shall designate by written
notice to the other. Any such notice, instruction or communication shall be
deemed given when actually received or, if earlier, five days after deposit in
the United States Mail or two business days after deposit with an air courier.

         11.2 PAYMENTS. All payments to Safetech shall be remitted by cheek to
the order of Safetech at the address set forth in subsection 11.1.

         11.3 NOTICE OF LITIGATION. Safetech shall promptly notify Retrac of the
commencement of any litigation or of any Patent and Trademark Office proceeding
involving the Patents after the granting or issuance thereof.

                                   ARTICLE XII
                              TERM AND TERMINATION

         12.1 TERM. The term of the License shall be until all of the Patents
have expired, become invalid, or become unenforceable, and thereafter for so
long as Licensed Products are being sold by Retrac.

         12.2 EFFECT OF TERMINATION. Upon termination of this Agreement all
obligations between the parties shall cease, except the confidentiality
obligations of Article VII, which shall survive this Agreement.

                                  ARTICLE XIII
                                     GENERAL

         13.1 TRANSFERABILITY. Retrac may assign or transfer the license rights
granted herein at its sole discretion. Safetech may not assign, sell,
hypothecate or otherwise transfer or encumber its rights under this Agreement
without the prior written permission of Retrac.

         13.2 INTEGRATION. This Agreement constitutes the entire understanding
of the parties and may not be modified or amended except by an instrument in
writing executed by the parties hereto which expressly states that it is an
amendment hereto.

                                       6
<PAGE>

         13.3 MODIFICATION. No modification to this Agreement, nor any waiver of
any rights, shall be effective unless consented to in a writing which references
this Agreement and the waiver of any breach or default shall not constitute a
waiver of any other right or any subsequent breach or default. No modification
of the terms of this Agreement by Addendum, Exhibit, or otherwise shall be
effective unless executed by both parties, hereto.

         13.4 BINDING EFFECT. This Agreement shall be binding upon and inure to
the benefit of the respective heirs, successors, assigns and legal
representative of each party.

         13.5 FORCE MAJEURE. Neither party shall be liable for any loss, expense
or damage caused by delays in performance resulting from acts of God, supplier
delay or any other cause beyond the reasonable control of Safetech or Retrac.

         13.6 SEVERABILITY. Should a court of competent jurisdiction later
consider any provision of this Agreement to be invalid, illegal or
unenforceable, it shall be considered severed from this Agreement. All other
provisions, rights and obligations shall continue without regard to the severed
provision, provided that the remaining provisions of this Agreement are in
accordance with the intention of the parties.

         13.7 LEGAL CONSTRUCTION: JURISDICTION. Except to the extent otherwise
agreed to in writing by the parties, this Agreement and the performance, rights
and obligations of the parties hereunder shall be governed and interpreted in
accordance with the laws of the State of New York and the United States of
America. The parties consent to the personal and exclusive jurisdiction of New
York federal and state courts for Rockland County, as applicable.

         13.8 ADVICE OF COUNSEL. The parties acknowledge that prior to execution
of this agreement they have had the opportunity to fully consult with their
respective counsel regarding this agreement and that they understand all the
terms, obligations, conditions and consequences herein and accept the same.

         13.9 RECORDATION. The panics agree to execute an acknowledgment of this
License Agreement for recordation in the US Patent Office.

         13.10 CONFIDENTIALITY OF AGREEMENT. The parties agree that there will
be no public disclosure of the financial terms of this Agreement except as
required by law, Court or government agency.

         13.11 HEADINGS. The headings and subheadings of the various Articles
and Sections of this Agreement are inserted merely for the purpose of
convenience and do not express or imply any limitation, definition (except
Article II) or extension of the specific terms of the Article and Section so
designated.

                                       7
<PAGE>

         IN WITNESS WHEREOF each of the parties has caused this Agreement to be
executed in duplicate originals by its duly authorized representative.

Executed:  June 15th, 2000

                                        Safe Tech Medical Products, Inc.

                                        By /s/ Michael L. Haining
                                           ---------------------------------
                                            Michael L. Haining

                                        Michael L. Haining.

                                        /s/ Michael L. Haining
                                        -----------------------------

                                        Retrac Medical, Inc.

                                        By /s/ Martin Kelly
                                           ---------------------------------
                                           Martin Kelly, President/CEO

                                       8
<PAGE>

               EXHIBIT A TO PATENT LICENSE AND TRADEMARK AGREEMENT

United States Patents:

         5,401,245
         5,527,306
         5,785,693
         5,533,983

International Application

         PCT/US95/15761

Corresponding Foreign National Applications

         Canada                             2 204 048
         European Patent Office             95 942 548.9
         Japan                              517 712/1996
         Mexico                             974 237
         People's Republic of China         95 197 269.3EXHIBIT 10.5

                              SETTLEMENT & RELEASE
                                    AGREEMENT

         THIS SETTLEMENT AND RELEASE AGREEMENT (the "Agreement") dated June 1st,
1996 with an effective date of April 17th, 1996, is made and entered into by and
among Faithful Investments & Holdings Ltd. with its corporate address at Trident
Chambers Wickhams Clay, PO Box 146 Road Town, Tortola BVI ("FIHL") and Re-Track
USA, Inc. a Delaware corporation having its principal corporate address at 8
Bruce Court Montebello, New York 10901 ("Re-Track").

                                    RECITALS

         WHEREAS, Faithful Investments & Holdings Ltd. is party to a certain
loan and services agreement pursuant to which FIHL provided services (the
"obligations") to Safe Tech Medical Products, Inc. (STMP), which services
included, but were not limited to the providing of a monetary loan, legal
assistance and advisory services.

         WHEREAS, Re-Track USA, Inc. desires to be a party to a certain license
agreement dated April 16th 1996 (the "License Agreement") pursuant to which
Re-Track obtained certain rights to patents and patent applications (the
"patents") from Safe Tech Medical Products, Inc. ("STMP").

         WHEREAS, Re-Track USA, Inc. desires to obtain a release from Faithful
Investments & Holdings Ltd. of any and all claims it may have against Safe Tech
Medical Products Inc., the patents and patent applications under the new license
agreement.

         NOW THEREFORE, in consideration of the representations, warranties and
covenants of the respective parties herein, and for good and valuable
consideration, the receipt and sufficiency of which is hereby acknowledged, the
parties hereto agree as follows.

         1. TERMINATION OF ALL PRIOR AGREEMENTS. FIHL agrees to terminate all
past and present agreements both oral and written between STMP and itself, in
return for the consideration as set forth in item 2 below and further agrees to
hereby release and forever discharge STMP, their affiliates, subsidiaries and
divisions, their respective officers and directors from any and all claims,
demands, damages, causes of action or suits, whether in contract, tort, equity,
statute or otherwise that it may have, have ever had or may potentially have as
of the beginning of time to date hereof.

         2. PAYMENTS AND OTHER CONSIDERATION TO FIHL. In consideration for FIHL
terminating the above agreements Re-Track will provide for the following
consideration.

                  a) On the signing and execution of this agreement and the
delivery of the same, Re-Track shall make and deliver to FIHL an unsecured
promissory note, in the form attached hereto appendix A (the "note") in the
principal total amount of $555,000 which amount are calculated as follows,
$165,000, $390,000, for loans and services respectively provided to STMP.

                                       1
<PAGE>

                  b) On the signing and execution of this agreement and the
delivery of the same, FIHL hereby subscribes to purchase and Re-Track agrees to
sell and issue an aggregate of 135,000 Shares (the "Shares") of common stock,
par value $0.01 per share (the "Common stock") of Re-Track USA, Inc. The
aggregate purchase price to be paid by FIHL for the shares shall be $1,350 in
cash, representing the aggregate par value of the shares, the payment of which
will be deducted from the principal of the unsecured promissory note to be
issued to FIHL.

                  c) On the signing and execution of this agreement and the
delivery of the same, Re-Track shall make and deliver to FIHL an option
agreement in the form attached hereto appendix B (the "option") to purchase a
total of 1000,000.00 Shares of Re-Track common stock at an aggregate purchase
price of $0.01 per Share. The option agreement shall be for a term of one year
from the date of this agreement. In the event that FIHL, exercises the option
the payment for the Shares will be provided for by reducing the principal
balance due FIHL under the terms of the unsecured promissory note. The aggregate
purchase price for the option Shares to be paid by FIHL is $10,000 representing
the par value of the Shares.

         3. REPRESENTATIONS AND COVENANTS OF THE PARTIES. Each of the parties
hereto represent, warrant covenant to one another that:

                  a) AUTHORITY. Each party has the power and authority to
execute and deliver this agreement to which it is a party, and to perform its
obligations hereunder and has been duly authorized, and once executed and
delivered it will be binding and enforceable against it in accordance with the
terms herein.

                  b) NO PENDING ACTIONS. Each party warrants that there are no
actions, suits, proceedings or investigations pending or threatened in any court
or before any governmental agency, by or affecting it or any of its subsidiaries
or their business, operations or financial condition or any of their properties
or assets, or which would prevent the carrying out of this agreement or any part
of the transaction contemplated hereby or declare the same unlawful or cause the
transaction thereof.

                  c) FURTHER DOCUMENTS. Each party warrants to execute such
other documents and instruments as counsel for the Re-Track reasonably deems
necessary to effect the compliance of the issuance of the Shares, Shares
underlying the option and the note with federal and state laws and to enforce
the compliance and intent of this agreement.

                                       2
<PAGE>

         4. REPRESENTATIONS AND COVENANTS OF FIHL: FIHL, represents, warrants
and covenants to Re-Track that:

                   a) REGISTRATION OF SHARES AND NOTE. FIHL understands that
neither the Shares, Shares underlying the option or the note have been
registered under the Securities Act of 1993, as amended (the "Securities Act"),
are issued in reliance on an exemption therefrom for transactions not involving
any public offering, that neither the Shares, Shares underlying the option or
the note have been approved nor disapproved by the Securities and Exchange
Commission or by any other Federal or State agency that,

                  b) REGULATION S MATTERS. (i) FIHL is not a US person as that
term is defined under Regulation S; (ii) at the time of this transaction was
negotiated, FIHL was outside of the United States and is outside the United
States as of the date of execution and delivery of this agreement and will
remain so on the date of the issuance of Shares, Shares underlying the option
and the note, (iii) FIHL is purchasing the Shares and the option Shares for its
own account and not on behalf of any US person, and no sale has been prearranged
with a purchaser in the United States, (iv) all offers and sales of the Shares
prior to the expiration of the 40 day time period contained in Regulation S
shall only be made in compliance with the safe harbor contained in Regulation S,
pursuant to registration of the Shares under the Act, or pursuant to an
exemption from the registration.

                  c) RISKY INVESTMENT. FIHL acknowledges that its investment in
the Shares and the Shares underlying the option involve a high degree of risk
and further acknowledges that it can bear the economic risk of such investment,
including the total loss thereof.

                  d) EXEMPT OFFERING. FIHL understands the Shares and the Shares
underlying the option are being offered and sold to it in reliance on specific
exemptions from the registration requirements of the federal and state
securities laws and that Re-Track is relying upon the truth and accuracy of
these representations, warranties and undertakings in order to determine the
applicability of such exemptions and the suitability of FIHL to acquire the
shares.

                  e) SHARES BEEN ACQUIRED. FIHL is acquiring the Shares the
Shares underlying the option and the Note for its own account for investment
purposes only and not with the view to sale of distribution thereof.

                  f) AUTHORITY. FIHL has the power and authority to enter into
this agreement and to perform any obligations it may have herein.

                  g) LIMITED OPERATIONS. FIHL acknowledges, (i) Re-Track has
been recently organized, (ii) Re-Track has a limited operating history, (iii)
all documents and books pertaining to Re-Tracks business has been provide to
FIHL, and or an FIHL accountant/representative, (iv) FIHL has had an opportunity
to ask questions and receive answers from Re-Track concerning the business and
assets of Re-Track and all such other questions have been answered to the full
satisfaction of FIHL and (v) FIHL is an accredited investor, as that term is
defined in Regulation D under the Securities Act.

                                       3
<PAGE>

         5. REPRESENTATIONS AND COVENANTS OF RE-TRACK. Re-Track represents
warrants and covenants to FIHL that,

                  a) COOPERATION. It will cooperate reasonably and timely with
FIHL in order to enable FIHL to perform any obligations which it may or may not
have pursuant to this agreement.

                  b) SHARES FREE OF LIENS, VALIDLY ISSUED. The Shares, as well
as the shares underlying the option will be free and clear of all liens,
charges, and encumbrances whatsoever, except as provided for herein, and will be
validly issued, fully paid and none assessable.

                  c) RE-TRACK PERFORMANCE. The performance by Re-Track of this
agreement will not violate any court decree, law or regulation, nor will it
violate any provisions of the organizational documents of Re-Track, nor any
other contractual obligation by which Re-Track is bound.

                  d) REGULATION S MATTERS. If in the event that Re-Track becomes
a reporting company, as defined by Rule 902 of Regulation S, it will remain in
full compliance, to the extent applicable, with all reporting obligations under
Section 13(d) or 15(d) as applicable of the Securities and Exchange Act of 1934,
as amended (the "Exchange Act"). The Shares to be offered and sold to FIHL
pursuant to Regulation S will be made in an "Offshore Transaction") as defined
by Rule 902 of Regulation S, and Re-Track will not conduct any "directed selling
efforts" as defined by Rule 902 of Regulation S, nor will Re-Track conduct any
general solicitation relating to the offer and sale of the securities to persons
resident within the United States or elsewhere.

                  e) AUTHORITY. Re-track has the power and authority to enter
into this agreement and to perform all of its obligations herein.

         6. ASSIGNMENT. This agreement shall be binding upon and inure to the
benefit of the parties named herein and their respective successors and
permitted assigns. Neither party may assign either this agreement or any of its
rights, interest, or obligations hereunder without the prior written approval of
the other party, which such approval will not be unreasonably withheld.

         7. AMENDMENTS AND WAIVERS. No amendment of any provision of this
agreement shall be valid unless the same shall be in writing and signed by each
party. No wavier by either party of any default, misrepresentation, or breach of
warranty or covenant hereunder, whether intentional or not shall be deemed to
extend to any prior or subsequent default, misrepresentation, or breach of the
warranty or covenant hereunder or effect in any way the fights arising by virtue
of any prior or subsequent such occurrence.

                                       4
<PAGE>

         8. NOTICES. All notices required under the terms of this agreement will
be deemed served only if such notice has been sent by, (i) registered certified
mail, (ii) return receipt requested, (iii) postage prepaid, (iv) one business
day after it is sent via a reputable overnight courier service and (v) all
notices to be sent to the official corporate address of each party as may exit
at that time as such notice was sent.

         9. GOVERNING LAW. This agreement shall be governed by and construed in
accordance with the laws of the British Virgin Islands.

         IN WITNESS WHEREOF, the parties hereto have executed this agreement as
of the date first above written.

RE-TRACK USA, INC.

/S/ Martin Kelly
----------------
Martin Kelly
President CEO

FOR AND ON BEHALF OF
FAITHFUL INVESTMENTS & HOLDINGS LTD.

/S/ Martin Kelly
----------------
Martin Kelly
Attorney In fact

                                       5
<PAGE>

                                                                      APPENDIX A

                               RE-TRACK USA, INC.
                            UNSECURED PROMISSORY NOTE

$555,000USD                                                       JUNE 1ST, 1996

                  FOR VALUE RECEIVED, the undersigned, Re-Track USA, Inc., a
Delaware corporation (the "Maker") hereby promise's to pay to or to the order of
Faithful Investments & Holdings Ltd. a BVI corporation, (the "Holder"), or its
nominee the principal sum of Five Hundred and Fifty Five Thousand ($555,000.00).

The promissory will bear interest at a rate of 12% per annum to be paid annually
in arrears. The Maker shall repay the principal sum, or such lesser portion
thereof as remains unpaid and outstanding hereunder from time to time (the
"Outstanding Amount") on or before the close of business, Eastern Standard Time,
on May 31st, 2001 or within 15 days of completion of an Initial Public Offering
that provides for a minimum net proceeds of $5,000,000 to the Maker.

This unsecured promissory is not secured by any of the assets of the Maker and
in the event of a default by the Maker the Holder will have no rights to
securing of the assets in an attempt to collect against the Maker.

The Outstanding Amount may be pre-paid by the Maker, in whole or in part, at its
election and without penalty or premium, at any time prior to the maturity date,
provided however that the Maker shall pre-pay a minimum of $50,000.00 per year
to the Holder such amount to be deducted from any accrued interest first the
balance thereof that deducted from the principal.

All payments due under this unsecured promissory note shall be paid in lawful
money of the USA during regular business hours of the Holder, and at such place
as the Holder may at any time or from time to time designate in writing to the
Maker.

If the Maker fails to make payment in full of the indebtedness evidenced hereby
on or before the maturity date, or if the Maker fails to make any other payments
of principal on or before the date on which such payment is required to be made
hereunder, the Holder may, at its sole option with notice to the Maker, declare
immediately due and payable the entire unpaid principal balance of this
unsecured promissory note.

If any provision hereof should be held unenforceable or void, them such
provision shall be deemed separable from remaining provisions hereof and shall
in no way affect the validity of this note, except that if such provision
relates to the payment of any monetary sum, then the Holder mat at its option
declare the indebtedness evidenced hereby immediately due and payable.

                                       6
<PAGE>

All changes to or additions to this note may be made or compliance with any term
covenant, agreement, condition or provision set forth herein may be omitted or
waived or in a particular instance and either or retroactively or prospectively,
only upon written consent of the Maker and the Holder.

This note shall be governed under the laws of the British Virgin Island.

IN WITNESS WHEREOF, this Unsecured Promissory Note has been executed and
delivered on the date first written above and in accordance with the agreement
attached hereto, by a duly authorized officer of the Maker.

RE-TRACK USA, INC.

/S/ Martin Kelly
----------------
Martin Kelly
President CEO

                                       7

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00015-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00015-of-00352.parquet"}]]